Compare ImmunityBio Inc. Common Stock (IBRX) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Block Inc — how do they compare? ImmunityBio Inc. Common Stock trades at $10.46 (market cap $10.51B), while Block Inc trades at $76.6 (market cap $45.20B). The key difference: Block Inc is far larger — about 4.3× ImmunityBio Inc. Common Stock's market cap, and ImmunityBio Inc. Common Stock is trading nearer its 52-week high, Block Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Block Inc for 78 Days on average.
| IBRX | XYZ | |
|---|---|---|
Market Cap | $10.51B | $45.20B |
Volume | 10,445,785 | 8,386,094 |
Sector | Health | Technology |
52-Week High | $11.55 | $84.85 |
52-Week Low | $1.98 | $49.04 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $10.97B | $40.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYZ (Block Inc.) trades at $76.07, down 0.64% today, with a bearish technical signal despite strong analyst support. The stock shows mixed fundamentals with a high P/E ratio of 134.34 but solid revenue growth from $24.19B in 2025 to projected $25.0B in 2026. Recent earnings beats in Q1 and Q2 2026 contrast with Q4 2025's miss, while net income margin compression from 12.01% to 1.42% raises profitability concerns. Positive developments include Square platform expansions and potential federal trust bank approval.
XYZ presents a conflicted investment case with Wall Street optimism (76.9% buy ratings, $97.47 target) offset by valuation concerns and margin pressure. Near-term catalysts include Q3 2026 earnings on November 3, 2026, and banking charter progress. Key risks include intense fintech competition, execution challenges in Bitcoin operations, and insider selling activity. The stock trades near support at $75 with resistance at $77, requiring earnings acceleration to justify premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
